Taurine concentrations in congestive heart failure

Science (New York, N.Y.)
|June 14, 1974
PubMed

Insights

Taurine levels in heart muscle double in patients with chronic congestive heart failure and hypertensive rats. This elevation was specific to cardiac tissue, not seen in aortic or brain tissue.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pathology

Background:

  • Congestive heart failure (CHF) is a complex cardiac condition.
  • Taurine is an amino acid found in high concentrations in cardiac muscle.
  • The role of taurine in cardiac pathology is not fully understood.

Purpose of the Study:

  • To investigate the relationship between taurine concentration and chronic congestive heart failure.
  • To examine taurine levels in cardiac and non-cardiac tissues under hypertensive conditions in an animal model.

Main Methods:

  • Comparative analysis of left ventricular myocardial and aortic tissue taurine concentrations in human patients with and without CHF.
  • Induction of stress and observation of naturally occurring hypertension in rat models (Okamato strain).
  • Measurement of taurine concentrations in cardiac, skeletal muscle, and brain tissues of hypertensive and control rats.

Main Results:

  • Human patients with CHF exhibited approximately double the concentration of taurine in left ventricular muscle compared to controls.
  • No significant difference in aortic tissue taurine levels was observed between the two human groups.
  • Stress-induced hypertension in rats led to increased cardiac taurine levels, with no significant alterations in skeletal muscle or brain taurine.
  • Spontaneously hypertensive rats showed elevated cardiac taurine levels compared to normotensive controls.

Conclusions:

  • Elevated cardiac taurine concentration is associated with chronic congestive heart failure in humans.
  • Hypertension, both induced and spontaneous, leads to increased taurine levels specifically within the heart muscle.
  • Taurine accumulation in cardiac tissue may be a compensatory mechanism or a consequence of cardiac stress and pathology.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.